Michael Trauner Selected Research

Obesity

11/2022	Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH.
1/2021	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD.
1/2020	Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
1/2018	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
1/2016	Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.
8/2015	The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Trauner Research Topics

Disease

153	Fibrosis (Cirrhosis) 03/2024 - 12/2005
123	Liver Diseases (Liver Disease) 04/2024 - 05/2002
86	Cholestasis 11/2023 - 01/2002
75	Inflammation (Inflammations) 03/2024 - 02/2006
56	Liver Cirrhosis (Hepatic Cirrhosis) 03/2024 - 11/2004
56	Non-alcoholic Fatty Liver Disease 01/2024 - 01/2010
51	Portal Hypertension 03/2024 - 07/2011
46	Hepatocellular Carcinoma (Hepatoma) 02/2024 - 04/2005
38	Sclerosing Cholangitis 11/2023 - 05/2003
32	Neoplasms (Cancer) 04/2024 - 04/2005
29	Fatty Liver 03/2024 - 02/2009
27	Infections 03/2024 - 05/2004
24	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 02/2024 - 04/2003
22	End Stage Liver Disease 08/2023 - 11/2009
19	Hemorrhage 02/2024 - 11/2013
16	Disease Progression 05/2023 - 11/2010
16	Insulin Resistance 01/2023 - 01/2010
15	Ascites 02/2024 - 01/2014
12	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023 - 01/2012
11	COVID-19 01/2023 - 01/2020
10	Hepatitis C 03/2024 - 03/2015
9	Acute-On-Chronic Liver Failure 01/2024 - 03/2007
9	Critical Illness (Critically Ill) 01/2023 - 01/2012
9	Chronic Hepatitis C 01/2018 - 04/2003
8	Cholangitis 03/2024 - 02/2006
8	Varicose Veins (Varicose Vein) 03/2024 - 11/2013
8	Carcinogenesis 01/2016 - 01/2007
7	Hepatic Encephalopathy 02/2024 - 01/2018
7	Hepatitis 01/2024 - 08/2005
7	Alcoholic Fatty Liver 11/2023 - 11/2004
7	Liver Failure 12/2022 - 10/2003
6	Adenoma (Adenomas) 04/2024 - 09/2011
6	Body Weight (Weight, Body) 03/2024 - 04/2003
6	Necrosis 11/2023 - 03/2005
6	Pruritus (Itching) 01/2023 - 04/2005
6	Obesity 11/2022 - 08/2015
6	Liver Neoplasms (Liver Cancer) 04/2022 - 01/2007
6	Acute Liver Failure (Fulminant Hepatic Failure) 01/2022 - 10/2003
6	Sepsis (Septicemia) 05/2021 - 10/2006
6	Cystic Fibrosis (Mucoviscidosis) 03/2020 - 01/2008
5	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 09/2011

Drug/Important Bio-Agent (IBA)

101	Bile Acids and Salts (Bile Acids)IBA 11/2023 - 01/2002
32	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 02/2024 - 05/2002
31	LipidsIBA 01/2023 - 01/2007
30	Biomarkers (Surrogate Marker)IBA 03/2024 - 08/2005
30	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 11/2023 - 05/2004
25	Proteins (Proteins, Gene)FDA Link 09/2023 - 04/2005
23	BilirubinIBA 02/2024 - 04/2005
19	CytokinesIBA 02/2024 - 03/2005
19	EnzymesIBA 09/2023 - 04/2005
19	LigandsIBA 08/2023 - 05/2004
18	4-(3-chlorophenylsulfanyl)piperidineIBA 03/2024 - 07/2011
17	Antiviral Agents (Antivirals)IBA 03/2024 - 07/2011
17	Triglycerides (Triacylglycerol)IBA 01/2023 - 02/2010
15	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2012
14	von Willebrand FactorIBA 03/2024 - 10/2012
14	InterferonsIBA 04/2022 - 07/2011
13	Alkaline PhosphataseIBA 02/2024 - 08/2008
13	C-Reactive ProteinIBA 01/2024 - 06/2013
12	AcidsIBA 11/2023 - 06/2009
11	CholesterolIBA 11/2023 - 05/2002
11	Hydroxyproline (4 Hydroxyproline)IBA 11/2023 - 08/2008
11	AlbuminsIBA 08/2023 - 10/2016
10	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 01/2011
10	gadolinium ethoxybenzyl DTPA FDA Link 12/2023 - 06/2014
10	Interleukin-6 (Interleukin 6)IBA 11/2023 - 04/2013
10	Messenger RNA (mRNA)IBA 11/2023 - 06/2006
10	Immunoglobulin G (IgG)IBA 05/2023 - 03/2012
10	Phospholipases (Phospholipase)IBA 01/2022 - 01/2012
9	Alanine Transaminase (SGPT)IBA 12/2022 - 04/2015
9	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020 - 01/2004
8	AntigensIBA 01/2024 - 10/2012
8	24-norursodeoxycholic acidIBA 11/2023 - 02/2006
8	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 06/2012
8	obeticholic acidIBA 12/2022 - 10/2011
8	Taurocholic Acid (Sodium Taurocholate)IBA 01/2018 - 01/2002
7	CollagenIBA 03/2024 - 02/2015
7	Transaminases (Aminotransferases)IBA 03/2024 - 09/2007
7	Therapeutic UsesIBA 03/2024 - 06/2009
7	SodiumIBA 10/2023 - 10/2007
7	LipopolysaccharidesIBA 08/2023 - 10/2009
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 07/2012
6	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 02/2024 - 07/2015
6	cilofexorIBA 11/2023 - 01/2019
6	Immunoglobulin M (IgM)IBA 05/2023 - 01/2016
6	TransferasesIBA 01/2023 - 02/2010
6	selonsertibIBA 01/2023 - 11/2019
6	AntibodiesIBA 01/2021 - 03/2009
6	Peptides (Polypeptides)IBA 01/2020 - 10/2007
6	CopperIBA 05/2019 - 11/2004
6	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 07/2011
6	ATP-Binding Cassette Transporters (ABC Transporters)IBA 10/2017 - 09/2003
6	Adenosine Triphosphate (ATP)IBA 10/2017 - 09/2003

Therapy/Procedure

63	Therapeutics 02/2024 - 04/2003
40	Liver Transplantation 10/2023 - 10/2003
19	Ligation 11/2023 - 06/2006
10	Transjugular Intrahepatic Portasystemic Shunt 12/2022 - 09/2017
8	Immunotherapy 02/2024 - 09/2016
7	Drug Therapy (Chemotherapy) 01/2021 - 04/2005
6	Surgical Portasystemic Shunt (Portosystemic Shunt) 12/2022 - 12/2017